Johnson S - Search Results

1

Estimation of impact of RPE65-mediated inherited retinal disease on quality of life and the potential benefits of gene therapy.

Lloyd A, Piglowska N, Ciulla T, Pitluck S, Johnson S, Buessing M, O'Connell T. Lloyd A, et al. Among authors: johnson s. Br J Ophthalmol. 2019 Nov;103(11):1610-1614. doi: 10.1136/bjophthalmol-2018-313089. Epub 2019 Jan 18. Br J Ophthalmol. 2019. PMID: 30658988 Free PMC article.

2

Estimating Alzheimer's Disease Progression Rates from Normal Cognition Through Mild Cognitive Impairment and Stages of Dementia.

Davis M, O Connell T, Johnson S, Cline S, Merikle E, Martenyi F, Simpson K. Davis M, et al. Among authors: johnson s. Curr Alzheimer Res. 2018;15(8):777-788. doi: 10.2174/1567205015666180119092427. Curr Alzheimer Res. 2018. PMID: 29357799 Free PMC article.

3

Tight control for Crohn's disease with adalimumab-based treatment is cost-effective: an economic assessment of the CALM trial.

Panaccione R, Colombel JF, Travis SPL, Bossuyt P, Baert F, Vaňásek T, Danalıoğlu A, Novacek G, Armuzzi A, Reinisch W, Johnson S, Buessing M, Neimark E, Petersson J, Lee WJ, D'Haens GR. Panaccione R, et al. Among authors: johnson s. Gut. 2020 Apr;69(4):658-664. doi: 10.1136/gutjnl-2019-318256. Epub 2019 Jul 8. Gut. 2020. PMID: 31285357 Free PMC article. Clinical Trial.

4

Cost-effectiveness of Voretigene Neparvovec-rzyl vs Standard Care for RPE65-Mediated Inherited Retinal Disease.

Johnson S, Buessing M, O'Connell T, Pitluck S, Ciulla TA. Johnson S, et al. JAMA Ophthalmol. 2019 Oct 1;137(10):1115-1123. doi: 10.1001/jamaophthalmol.2019.2512. JAMA Ophthalmol. 2019. PMID: 31318398 Free PMC article.

5

Important Considerations in Modeling the Cost-Effectiveness for the First Food and Drug Administration-Approved Gene Therapy and Implications for Future One-Time Therapies.

Buessing M, O'Connell T, Johnson S, Pitluck S, Ciulla TA. Buessing M, et al. Among authors: johnson s. Value Health. 2019 Aug;22(8):970-971. doi: 10.1016/j.jval.2018.12.013. Epub 2019 May 25. Value Health. 2019. PMID: 31426938 Free article. No abstract available.

6

Cost-Utility Analysis of Ravulizumab Compared with Eculizumab in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria.

O'Connell T, Buessing M, Johnson S, Tu L, Thomas SK, Tomazos I. O'Connell T, et al. Among authors: johnson s. Pharmacoeconomics. 2020 Sep;38(9):981-994. doi: 10.1007/s40273-020-00929-z. Pharmacoeconomics. 2020. PMID: 32519233

7

Cost-Effectiveness of Chimeric Antigen Receptor T Cell Therapy in Patients with Relapsed or Refractory Large B Cell Lymphoma: No Impact of Site of Care.

Cummings Joyner AK, Snider JT, Wade SW, Wang ST, Buessing MG, Johnson S, Gergis U. Cummings Joyner AK, et al. Among authors: johnson s. Adv Ther. 2022 Aug;39(8):3560-3577. doi: 10.1007/s12325-022-02188-0. Epub 2022 Jun 11. Adv Ther. 2022. PMID: 35689726 Free PMC article.

8

Indirect treatment comparison of oral versus injectable azacitidine as maintenance therapy for acute myeloid leukemia.

Tabah A, Huggar D, Wang ST, Johnson SJ, Copher RM, O'Connell T, McBride A, LeBlanc TW. Tabah A, et al. Future Oncol. 2022 Dec 12. doi: 10.2217/fon-2022-0820. Online ahead of print. Future Oncol. 2022. PMID: 36507931 Free article.

9

Assessing the Value of Artificial Intelligence in Retinopathy of Prematurity Screening-Be Specific With Regard to the Data.

Johnson SJ. Johnson SJ. JAMA Ophthalmol. 2022 Apr 1;140(4):409-410. doi: 10.1001/jamaophthalmol.2022.0222. JAMA Ophthalmol. 2022. PMID: 35297956 No abstract available.

10

Cost-Effectiveness of Brexanolone Versus Selective Serotonin Reuptake Inhibitors for the Treatment of Postpartum Depression in the United States.

Eldar-Lissai A, Cohen JT, Meltzer-Brody S, Gerbasi ME, Chertavian E, Hodgkins P, Bond JC, Johnson SJ. Eldar-Lissai A, et al. Among authors: johnson sj. J Manag Care Spec Pharm. 2020 May;26(5):627-638. doi: 10.18553/jmcp.2020.19306. Epub 2020 Mar 19. J Manag Care Spec Pharm. 2020. PMID: 32191592 Free PMC article.

OBJECTIVE: To estimate the cost-effectiveness of BRX compared with treatment with selective serotonin reuptake inhibitors (SSRIs) for PPD. METHODS: We projected costs (2018 U.S. dollars) and health (quality-adjusted life-years [QALYs]) for mothers treated with BRX or SSRIs …

OBJECTIVE: To estimate the cost-effectiveness of BRX compared with treatment with selective serotonin reuptake inhibitors (SSRIs) for PPD. M …

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

11,862 results

Search Page